Ferrocene-modified covalent organic frameworks combine sonodynamic therapy with immune activation to suppress primary breast ...

Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.

Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...

Bone is a common site for metastasis of solid cancers, but histological and molecular features of bone metastases are not well understood. In a new study published in Cell Genomics, researchers at ...

Results suggest bone-protecting agents should be used in patients with metastatic castration-resistant prostate cancer and bone metastasis, especially in the era of androgen receptor pathway ...

A recent study has uncovered the molecular mechanisms behind osteocyte death in melanoma bone metastasis, revealing that ferroptosis—an iron-dependent form of cell death—plays a central role in the ...

Detecting whether osteosarcoma, a rare but aggressive bone cancer that most often affects children and adolescents, has ...

New findings from VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM), published in Pharmacological Research, show that an innovative drug effectively prevents ...

Melanoma, one of the most aggressive forms of skin cancer, often metastasizes to bones, causing severe bone loss, an increased risk of fractures, and significant pain. Bone metastasis is associated ...

Oregon Health & Science University has received more than $9 million in National Institutes of Health funding to develop ...

Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...